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Aims: To identify, characterize and compare all Food and Drug Administration (FDA)
and European Medicines Agency (EMA) approvals that included real-world data on
efficacy from expanded access (EA) programmes.
Methods: Cross-sectional study of FDA (1955–2018) and EMA (1995–2018) regula-
tory approval documentation. We automated searching for terms related to EA in
22,506 documents using machine learning techniques. We included all approvals
where EA terms appeared in the regulatory documentation. Our main outcome was
the inclusion of EA data as evidence of clinical efficacy. Characterization was based
on approval date, disease area, orphan designation and whether the evidence was
supportive or pivotal.
Results: EA terms appeared in 693 out of 22,506 (3.1%) documents, which
referenced 187 approvals. For 39 approvals, data from EA programmes were used to
inform on clinical efficacy. The yearly number of approvals with EA data increased
from 1.25 for 1993–2013 to 4.6 from 2014–2018. In 13 cases, these programmes
formed the main evidence for approval. Of these, patients in EA programmes formed
over half (median 71%, interquartile range: 34–100) of the total patient population
available for efficacy evaluation. Almost all (12/13) approvals were granted orphan
designation. In 8/13, there were differences between regulators in approval status
and valuation of evidence. Strikingly, 4 treatments were granted approval based
solely on efficacy from EA.
Conclusion: Sponsors and regulators increasingly include real-world data from EA
programmes in the efficacy profile of a treatment. The indications of the approved
treatments are characterized by orphan designation and high unmet medical need.
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1 | INTRODUCTION
Patients suffering from seriously debilitating or life-threatening condi-
tions who are not eligible for further treatments or any clinical trials,
may resort to expanded access (EA): preapproval access to investiga-
tional treatments. EA, also known as early access, preapproval access or
compassionate use,1 is the formal regulation adopted by the Food and
Drug Administration (FDA) in 1987,2 propelled by the human immu-
nodeficiency virus (HIV)/acquired immunodeficiency syndrome crisis.
In the USA, the FDA regulates this process of formalized non-clinical
trial access while in the European Union (EU) the responsibility lies
with individual member states.3 The exact conditions, types (single
patient, group, protocolized, emergency) and definitions of EA vary
between member states.4 The numbers of requests for EA are grow-
ing5 and state and federal legislation, such as Right-to-Try laws in the
US, stress the need and interest of patients in having earlier access to
medicines that are still under clinical investigation.
Also of interest, and closely related to EA, is the field of real-
world data (RWD). RWD are “information on health care that is
derived from multiple sources outside typical clinical research set-
tings”.6 Recent publications and regulatory frameworks have boosted
the promise of RWD.7–9 It can come in many forms and shapes, such
as electronic health records, social media or claims databases.
EA programmes are generally considered to be a source of
RWD.10 Historically, however, EA programmes were only deemed fit
for treatment and not for research. Although the primary purpose of
EA is treatment, scholars have argued that there is a moral obligation
to collect outcome data in all cases where patients are treated with
investigational medicine.11–13 The debate on combining data collec-
tion and EA has substantially increased,14–16 with FDA officials con-
firming, beginning 2018, their willingness to review data from EA
programmes to support drug applications.11
Considering the increasing interest in both EA and RWD, the
question arises of whether alternative routes of access to novel treat-
ments can provide clinical information and impact regulatory decision
making. In this research, we systematically assess the role of RWD
from EA programmes in the regulatory approval process of the FDA
and the European Medicines Agency (EMA), comparing and character-
izing all approvals that utilize RWD on efficacy from EA programmes.
2 | METHODS
In the USA, the FDA oversees both EA programmes and marketing
authorizations. In the EU, EA is supervised by individual member
states, whereas marketing authorizations are granted by the EMA via
the centralized procedure. Therefore, to obtain an overview of
whether data from EA programmes were used for submissions, we
downloaded the Drugs@FDA database17 and the EMA medicines
overview18 on 1 May 2019. For the FDA database, we downloaded
the application documents (labels and reviews) associated with all
approvals available in the database. Next, we retrieved documents
from the drug approval packages sites. For the EMA, for each
approved drug, we saved the scientific discussion, label and/or public
assessment report that are listed in the database. Figure 1 gives a
schematic overview of our method.
As some of the FDA documents are scanned files, we first per-
formed optical character recognition using Google's Tesseract
engine,19 to extract text from the scans and subsequently process the
extracted text.
To find candidate documents, i.e. documents that mention EA, we
searched for the related terms: compassionate use, expanded access,
early access, preapproval access, named patient and managed access.
We expected these terms to appear if the data from an associated EA
programme were used in the submission package. When at least 1 of
these terms appeared in the document, the associated submission
package possibly included EA data for the approval. Therefore, we
assessed these candidates manually to determine whether data from
EA were used in a supportive/pivotal manner, or whether the mention
of EA-related terms was not in support of efficacy. The manual
assessment was performed by T.B.P. and in case of doubt discussed
with C.A.U.-d.G.
As all (preapproval) data concerning patient safety are reported
for purposes of pharmacovigilance, we focused on data from efficacy.
Patients in EA programmes are never randomized, and the absence of
a direct control group makes it challenging to draw sound conclusions
on efficacy. Nonetheless, this makes it even more attractive to under-
stand the reasons that led to acceptance of EA programmes as source
of evidence.
What is already known about this subject
• Patients are demanding speedier access to investigational
treatments.
• Industry and regulators are increasingly incorporating
data collected outside of clinical trials in decision making.
• Little is known about how, why and whether real-world
data from expanded access may lead to regulatory
approvals.
What this study adds
• Techniques from artificial intelligence can be applied to
process approval documentation for health policy
analyses.
• Real-world data from expanded access programmes are
increasingly accepted as evidence by regulators when col-
lecting data in controlled settings is infeasible.
• Thirty-nine Food and Drug Administration/European
Medicines Agency approvals rely on real-world data from
expanded access programmes to constitute the efficacy
profile of a treatment. In 4 cases, these data were the sole
source of evidence.
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Duplicates are removed from our data set. Duplication in this
sense occurs when an approved treatment consists of multiple (recur-
ring) compounds and the underlying data is duplicated. If no new data
from EA were used, we removed such duplicates.
To determine whether EA data were included in the clinical effi-
cacy profile, we followed 2 criteria. First, the data from the EA
programme must have been mentioned under the section clinical effi-
cacy in the medical/summary review (FDA) or scientific dis-
cussion/public assessment report (EMA). In addition, we studied the
impact of the evidence. If the EA data were mentioned under the piv-
otal/main studies, we considered the data to have a pivotal (P) level of
evidence. If not, we labelled the evidence as supportive (S). For all can-
didate documents, we considered related approved treatment.
Figure 2 illustrates our review procedure.
Finally, we further inspected the group of approvals that
included RWD from EA programmes in terms of disease areas,
orphan designation, timing of marketing approval and the number
of patients in the EA programmes relative (nEA) to the total number
of patients (N) in the trials. We used descriptive statistics to
describe our data set. To compare our subset of approvals to regu-
lar approvals with respect to the number of orphan designations,
F IGURE 1 Flowchart of automated candidate search. We
searched through all FDA and EMA documentation for expanded-
access related terms (compassionate use, expanded access, early access,
preapproval access, named patient and managed access). When these
terms appear, the document is considered a candidate. For scanned
files, optical character recognition was used
F IGURE 2 Flowchart of review process. We manually reviewed
and deduplicated 187 approvals related to the candidate documents.
All approvals that used expanded access (n = 39) to support clinical
efficacy were analysed. For 13 approvals, the evidence from
expanded access was the pivotal source of evidence
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we used χ2 tests with a 2-sided significance level of .05. To detect
a trend over time in the yearly numbers of approvals, we used a
Spearman rank correlation test with a 2-sided significance level of
.05.
3 | RESULTS
In total, 693 out of 22,506 scanned documents contained terms
related to EA. The number of documents is skewed between agen-
cies (2,508 EMA, 19,998 FDA), but this is mainly due to the nature
of documentation. The FDA database distinguishes between medi-
cal reviews, chemistry reviews, pharmacology reviews, microbiology
reviews, statistical review summary reviews and even all-version
updates thereof. The EMA merges the content of reviews in public
assessment reports and scientific discussions. These 693 documents
referenced 187 unique drug approvals, 126 from the FDA and
93 from the EMA (32 overlap). The FDA database contains docu-
mentation dating back to 1955. The first EMA documentation is
available since 1995.
As a first step, we removed 10 duplicates, leaving 177 approvals.
For example, the safety profile of tenofovir disoproxil mentions a
“compassionate use program”.20 This is repeated in all documentation
regarding highly active antiretroviral therapy in the treatment of HIV,
of which tenofovir disoproxil is part.
Second, we determined whether data from EA programmes was
used to back the profile of clinical efficacy of the treatment. This was
the case in 22% (39/177) of all approvals. The FDA considered effi-
cacy data in 25 cases, the EMA in 24 (10 overlapped). Interestingly,
nearly 3/4 (29/39) of these drugs were granted orphan designation.
We encountered the first use of RWD from EA in 1993. From the
beginning of 1993 to the end of 2013, the average number of
approvals that included EA-efficacy data per year was 1.24 (standard
deviation 1.09) vs 4.6 (standard deviation 1.14) from 2014–2018. We
observe a clear increase over the years with a Spearman correlation of
0.40 (P = .042). Figure 3 shows the distribution of these approvals by
the EMA and the FDA, alongside their level of evidence, in a Venn dia-
gram. Figure 4 displays the date of marketing authorization for these
approvals. The complete list of approvals can be found in the Supple-
mentary Files.
F IGURE 3 Venn-diagram of approvals where
the Food and Drug Administration (FDA) and/or
European Medicines Agency (EMA) relied on data
from expanded access programmes to form the
clinical efficacy profile. The level of evidence
associated to these data by either regulator could
be pivotal or supportive
F IGURE 4 Bar chart of dates of
marketing authorization of 25 Food and Drug
Administration (FDA) and 24 European
Medicines Agency (EMA) approvals that relied
on real-world data from expanded access for
the clinical efficacy profile
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3.1 | Expanded access as pivotal evidence
We further investigate the approvals where RWD from EA
programmes played a pivotal role. This was the case in 1 third (13/39)
of the group mentioned in the previous paragraph. Table 1 gives an
overview of these approvals. Twelve out of 13 received orphan desig-
nation. This is significantly higher if we compare it to regular
approvals. For example, EMA assigned orphan designation to 134 out
of 1,111 all-time approved drugs vs 12 out of 13 drugs in the pivotal
group (P < .0001). If we characterize by indication, just under half of
the approvals (6/13) concerned treatments for metabolic disorders.
The remainder are divided between haemato-oncology (3 indications),
infectious diseases (2 indications) and overdosing (2 indications), all
covering areas of high unmet medical need.
The median ratio of patients from EA programmes to the total
patient population (nEA/N) that pivotally reinforced the efficacy profile
was 71% (interquartile range: 34–100). In absolute terms, this varies
from only 2 (vestronidase alfa) up to 558 patients (lutetium
oxodotreotride). Even though this a small sample, the former 2 patients
formed 12% (2/17) of the total patient population in pivotal studies.
By contrast, 558 patients comprised 71% (558/787) of the total
patient population, meaning that almost 3/4 of the patient population
was treated under EA programmes. Although 558 is the largest num-
ber of patients we observed in the pivotal group, we have encoun-
tered EA programmes containing >13 000 patients (stavudine) that
provided information on efficacy with a supportive level of evidence.
3.2 | Expanded access as sole evidence
Strikingly, the evidence from EA programmes was the only evidence in
4 cases: (i) sodium phenylacetate and sodium benzoate (FDA);
(ii) uridine triacetate (FDA); (iii) cholic acid (FDA/EMA); and (iv)
nitisinone (FDA/EMA). We describe these approvals here in more
detail.
The combination of sodium phenylacetate and sodium benzoate
(i) is indicated for the acute treatment of hyperammonaemia in
patients with urea cycle disorders, a rare disorder causing dangerously
elevated ammonia levels. The observed treatment effect was consid-
erable; historical control data showed a 48% survival rate, whereas
80% of the patients treated under EA with sodium phenylacetate and
sodium benzoate survived.21
TABLE 1 Overview of all Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals that rely in a pivotal way
on real-world data from expanded access (EA) programmes
Generic name Indication FDAa EMA Studiesb nEA/N
c
Amphotericin B Fungal infections 1997 N 10 CT (n = 2038), 1 EA (n = 133) 0.06 (133/2171)
Anagrelide Essential thrombocythaemia 1997 2004 2 SACT (n = 35 + 254), 1EA (n = 245) 0.45 (245/538)
Cholic acid Inborn errors of bile acid
metabolism
2015 2015 2 EA (n = 63 + 22) 1.00 (85/85)
Clarithromycin Mycobacterium avium complex 1993 Nd 1 RCT (n = 154), 1 SACT (n = 25),
1 EA (n = 469)
0.72 (469/648)
Dinutuximab β Neuroblastoma Ne 2017 1 RCT (n = 370), 1 SACT (n = 44),
1 EA (n = 54)
0.12 (54/468)
Fish oil triglycerides Parenteral nutrition-associated
cholestasis
2018 N 1 SACT (n = 144), 1 EA (n = 37) 0.20 (37/181)
Glucarpidase Elevated metrotrexate levels 2012 W 1 SACT (n = 147), 1 EA (n = 22) 0.13 (22/169)
Lutetium
oxodotreotide
Neuroendocrine tumours 2018 2017 1 RCT (n = 229), 1 EA (n = 558) 0.71 (558/787)
Nitisinone Tyrosinaemias 2002 2005 1 EA (n = 207) 1.00 (207/207)
Sodium
phenylacetate/
benzoate
Acute hyperammonaemia
in urea cycle disorders
2005 N 1 EA (n = 316) 1.00 (316/316)
Uridine triacetate Fluoruacil or capeticabine
overdose
2015 N 2 EA (n = 75 + 60) 1.00 (135/135)
Velmanase α Alpha-mannosidosis N 2018 1 RCT (n = 25), 1 EA (n = 35) 0.58 (35/60)
Vestronidase α Mucopolysaccharidosis VII 2017 2018 2 SACT (n = 3 + 12), 1 EA (n = 2)f 0.12 (2/17)
aYear of EMA/FDA approval (if applicable). W: withdrawn; N: not approved.
bMain studies that provided information on efficacy. SACT = single arm clinical trial; EA = expanded access; (R)CT = (randomized) controlled trial.
cRatio of patients in expanded access (nEA) to total number of patients in main studies (N)
dClarithromycin is approved in individual member states, before the introduction of the centralized procedure.
eDinutixumab α is marketed in the USA (Unituxin) but not anymore in the EU (replaced by β). As α and β are not exactly equal, we opted not to compare α
and β.
fThe EMA did not consider the 2 patients in EA for clinical efficacy.
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Uridine triacetate (ii) treats patients following 5-fluoruoacil or
capecitabine overdose. Overdosing can lead to life threatening toxic-
ities; uridine triacetate was therefore administered under emergency
EA. Historical control data indicated that 16% of patients receiving
only supportive care survived. In the EA programme of uridine triace-
tate, survival rate was 97%.22
Cholic acid (iii) is approved for the life-long treatment of bile acid
synthesis disorders. It replaces the abnormal bile acids produced by
patients with inborn errors in primary bile acid synthesis. Effective-
ness was established by comparing changes in bile acid levels before
and after treatment. The submission package only included RWD
from EA programmes, because “the indications for which the product in
question is intended are encountered so rarely that the applicant cannot
reasonably be expected to provide comprehensive evidence, and that it
would be contrary to generally accepted principles of medical ethics to
collect such information.”23
Nitisinone (iv) is a treatment for hereditary tyrosinaemia type
1 and it prevents the flawed conversion of tyrosine. The EA pro-
gramme was coordinated from Sweden and patients were treated in
87 different hospitals in 25 countries. Marketing approval was granted
“in view of the rare occurrence and seriousness of the disease, the lack of
therapeutic alternatives and the obvious clinical efficacy.”24
4 | DISCUSSION
Having analysed all available approval documentation, we observe
that expanded access programmes can provide information on clinical
efficacy that impacts regulatory decision making. Furthermore, we
find that sponsors and regulators increasingly include RWD from EA
programmes in the efficacy profile of an approval package. The indica-
tions of these approvals are characterized by their orphan designation
and high unmet medical need, a specific group of conditions. Although
the use of RWD may seem a novel application, our study shows that,
in the case of EA, RWD was already used before the year 2000. The
EA programmes propelled by acquired immunodeficiency syndrome
activism already led to the use of RWD: in 1996, for abacavir (FDA) or
1997 for stavudine (EMA): both compounds are used in the manage-
ment of HIV.
The specific circumstances in which RWD can complement or
even substitute RCTs25–27 are in line with the motivations behind the
use of RWD from EA programmes. One of these conditions arises
when randomization is unethical, for example due to a large unmet
medical need.25 By design, this prerequisite is also a criterion of EA:
EA programmes are only for patients in dire need of unapproved
treatments. A second situation occurs when further randomized con-
trolled research is infeasible, e.g. when patient populations are small
due to low disease incidence.26 Our study shows that indeed, orphan
designations characterize RWD use from EA. As the rising interest in
personalized medicine results in sample sizes becoming even smaller,
data from EA may become increasingly important. Although in most
cases data collected from EA programmes complement data from con-
ventional clinical trials, in 4 approvals in our research, EA data were
the sole source of evidence. The absence of other approved therapies,
the rarity of the condition and the large observed treatment effect
formed the extraordinary circumstances that led to the approval with-
out evidence from (randomized) clinical trials. In particular conditions
it may be challenging to collect data in conventional highly controlled
settings and therefore collection of RWD from EA programmes may
be crucial.
Interestingly, there is no guidance on the collection and analysis
of data within EA programmes. This seems rather odd, as our results
show that RWD have been used for some time, there is an increasing
demand of patients and physicians for preapproval access to investi-
gational treatments, and, recently, pharmaceutical industry demanded
such guidance.28 Some European countries prohibit the collection of
data in an EA setting, stating that “no other data except
pharmacovigilance data can be gathered which will only be used for the
evaluation of the UMN (red: Unmet Medical Need/expanded access) pro-
gram.”29 Well-designed data collection in clinical trials should be con-
sidered a prerequisite for scientifically sound conclusions. EA
programmes harbour inherent flaws—such as data quality issues—and,
first and foremost, the lack of randomization. Although this should
always be kept in mind, it does not mean that the information from
patients treated under EA should simply be ignored. On the contrary,
various approvals rest on data from single-arm clinical trials.30
Although patients in EA programmes are not eligible for clinical trials,
this does not imply that their treatment data do not qualify for analy-
sis. Data from every patient could provide useful insights and more-
over, our study shows that the EMA has considered data from these
patients critical in specific approvals. A paradoxical situation arises
when individual member states do not allow RWD collection during
EA programmes, yet the EMA uses these RWD in decision making.
Harmonization across regulators and individual member states should
solve these paradoxes.
We encountered differences in regulatory decisions. In 7 cases,
the FDA considered data pivotal to the approval whereas the EMA
had not approved the product (6 cases) or the data were merely con-
sidered supportive (1 case). Conversely, the FDA has not (yet)
approved 2 products whereas the EMA has. Despite international
drug regulation harmonization efforts31,32 there is still room for regu-
latory cooperation across the Atlantic.
Considering our observations in a greater context it appears con-
ventional lines between treatment and research are becoming blurred.
This is true for both the field of RWD as a whole and for RWD from
EA in particular. An example of the former are administrative data
used for analyses: data that were not collected with the purpose of
research are now found at the heart of an analysis. Similarly for the
latter, where EA programmes were traditionally also meant exclusively
for treatment, data collection and thereby research has become a real-
ity. The changing position of EA patients from treatment subjects to
(partly) research subjects, provides a challenge for bioethicists.11,12,33
When it comes to comparisons between RCTs and RWD, both
have their merits. On the one hand, the control of variability and
assurance of data quality in RCTs leads to valid results. On the other
hand, these trials target specific homogenous patient populations,
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e.g. younger and with fewer comorbidities, which limits the generaliz-
ability of findings.26,27 RWD represents a more heterogenous or real-
life population, conclusions drawn on RWD are arguably more appli-
cable in day-to-day clinical settings.6,9 Finding the right balance
between RWD and RCTs can become an interesting topic for (bio)
statisticians, (pharmaco)epidemiologists, regulators and industry.
Awareness of the potential value of RWD from EA should facili-
tate that these data are used appropriately. This helps pharmaceutical
industry and regulators determine whether EA—and associated
RWD—is useful. For patients, this would hopefully result in speedier
access to more diverse treatments.
4.1 | Limitations and future research
Previous literature focused on the legal and ethical implications of
EA3,34–38 or attempted to characterize (US) EA programmes in terms
of associated clinical holds, impact on product labelling, acceptance
rates or dates of initiation.5,39–42 This study is the first to systemati-
cally identify, compare and categorize all EMA and FDA approvals that
rely on RWD from EA. This differs from previous literature comparing
approvals, focusing on the absence of randomized controlled trials.30
Additionally, to analyse the entire history of RWD use from EA, no
time limit was used. We are limited by the fact that the Drugs@FDA
database includes only drugs and therapeutics (no other biologics) and
consistently included reviews only after 1997.
Using recent advances in artificial intelligence to facilitate the
processing of documents, we were able to analyse many approvals.
As only approvals that appeared EA-related were assessed manu-
ally, the possibility remains that cases where EA data were in fact
used were missed because these terms did not appear in the docu-
mentation. Although it is unlikely that such terms would not
appear in relevant documents, our numbers therefore form a lower
bound of the real number of cases where EA data were used for
approvals.
Future research could focus on statistical implications of combin-
ing data from EA programmes and controlled trials. Additionally, we
have only investigated the use of EA efficacy data for regulators. Its
influence on other stakeholders such as payors or drug developers is a
subject that could be pursued through further research.
5 | CONCLUSION
EA programmes can generate real-world evidence prior to drug
approval. EMA and FDA increasingly utilize RWD from EA in
regulatory decision making. The treatments in these approval
decisions involved orphan designations and high unmet
medical need.
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